Advertisement
Advertisement
MLTX
MoonLake Immunotherapeutics Class A Ordinary Shares
18.34
USDSponsored
+0.55
+3.09%
Apr 17, 16:00 UTC -4
Closed
Pre-Market
18.16
-0.18
-0.95%
MLTX Earnings Reports
Positive Surprise Ratio
MLTX beat 9 of 15 last estimates.
60%
Next Report
Date of Next Report
May 07, 2026
Estimate for Q1 26 (Revenue/ EPS)
--
/-$0.90
Implied change from Q4 25 (Revenue/ EPS)
--
/-1.10%
Implied change from Q1 25 (Revenue/ EPS)
--
/+42.86%
MoonLake Immunotherapeutics Class A Ordinary Shares earnings per share and revenue
On Jan 08, 2026, MLTX reported earnings of -0.91 USD per share (EPS) for Q4 25, beating the estimate of -1.00 USD, resulting in a 9.03% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -2.96% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 11 analysts forecast an EPS of -0.90 USD, with revenue projected to reach -- USD, implying an decrease of -1.10% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Nurix Therapeutics, Inc. Common stock
Report Date
Apr 08, 2026 For Q1 26
Estimate
-$0.76
Actual
-$0.79
Surprise
-2.68%
NovaBridge Biosciences - ADR
Report Date
Apr 07, 2026 For Q4 25
Estimate
-$0.05
Actual
-$0.28
Surprise
-421.58%
KALA BIO, Inc. Common Stock
Report Date
Apr 15, 2026 For Q4 25
Estimate
-$1.46
Actual
-$0.67
Surprise
+54.38%
Scilex Holding Company Common Stock
Report Date
Apr 10, 2026 For Q4 25
Estimate
-$0.47
Actual
-$2.21
Surprise
-360.99%
Lexaria Bioscience Corp. Common Stock
Report Date
Apr 13, 2026 For Q2 26
Estimate
-$0.09
Actual
-$0.06
Surprise
+38.08%
Quince Therapeutics, Inc. Common Stock
Report Date
Apr 10, 2026 For Q4 25
Estimate
-$1.92
Actual
-$7.10
Surprise
-268.68%
GeoVax Labs, Inc. New
Report Date
Apr 15, 2026 For Q4 25
Estimate
-$6.29
Actual
$0.00
Surprise
+99.92%
FAQ
What were MoonLake Immunotherapeutics Class A Ordinary Shares's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, MoonLake Immunotherapeutics Class A Ordinary Shares reported EPS of -$0.91, beating estimates by 9.03%, and revenue of $0.00, 0% as expectations.
How did the market react to MoonLake Immunotherapeutics Class A Ordinary Shares's Q4 2025 earnings?
The stock price moved down -2.96%, changed from $18.22 before the earnings release to $17.68 the day after.
When is MoonLake Immunotherapeutics Class A Ordinary Shares expected to report next?
The next earning report is scheduled for May 07, 2026.
What are the forecasts for MoonLake Immunotherapeutics Class A Ordinary Shares's next earnings report?
Based on 11
analysts, MoonLake Immunotherapeutics Class A Ordinary Shares is expected to report EPS of -$0.90 and revenue of -- for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement